By Judith Wenshuk, peptide research writer
Quick Answer: Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue, studied primarily for its effects on visceral fat and growth hormone signaling. It has a more established clinical history than most compounds in the growth-hormone research category, including FDA approval in a prescription form for a specific indication.
Tesamorelin stands apart from most growth-hormone-related research peptides because it already has real clinical approval behind it — not for general use, but for a specific, well-documented application, which gives it a stronger evidence base than most compounds in this category. It’s available in Canada through research peptide suppliers for laboratory study.
How It Works
Tesamorelin is a GHRH analogue — it doesn’t supply growth hormone directly, but instead signals the pituitary gland to increase the body’s own natural growth hormone release. This indirect mechanism is a key difference from compounds like HGH itself, which supply growth hormone directly rather than stimulating its release.
What the Data Shows
Tesamorelin’s clinical trial history centers on visceral fat reduction — the deeper abdominal fat associated with metabolic risk, as distinct from subcutaneous fat. Trial data supporting its approved use showed measurable reductions in visceral fat over a six-month treatment period, with effects generally reversing after discontinuation, which is consistent with its mechanism of stimulating natural growth hormone release rather than making a permanent structural change.
Typical Research Protocol
Clinical use is typically studied as a once-daily subcutaneous administration, in contrast to the once-weekly protocols common to the GLP-1 family. Trial durations extended to six months and beyond, since visceral fat changes were measured as a gradual effect rather than an early, rapid one.
How It Compares to Other Growth-Hormone Compounds
Tesamorelin is often discussed alongside CJC-1295 and Ipamorelin, since all three relate to growth hormone signaling through different mechanisms. We’ve written a full comparison covering how Tesamorelin stacks up against CJC-1295/Ipamorelin, and a broader three-way comparison including HGH itself.
Frequently Asked Questions
Is Tesamorelin the same as HGH? No — Tesamorelin stimulates the body’s own growth hormone release, while HGH is the hormone itself, administered directly.
Does the visceral fat reduction last after stopping? Trial data generally shows effects reversing over time after discontinuation, consistent with its mechanism of stimulating a natural process rather than a permanent change.
Is Tesamorelin available as a research compound in Canada? Yes — Tesamorelin is available through research peptide suppliers in Canada as a laboratory research compound.
Leave a Reply